Latest Innovation News

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

DigitalX Limited's treasury reached a record A$75.9 million in May 2025, propelled by increased Solana holdings and enhanced staking yields. The company’s innovative approach balances Bitcoin’s stability with yield-generating digital assets.

Noxopharm’s Sofra™ technology has received promising external validation from BioRay Pharmaceutical, confirming its targeted anti-inflammatory potential and broad applicability in autoimmune disease therapies.

Johns Lyng Group has received a conditional, non-binding acquisition proposal from Pacific Equity Partners, sparking a potential shift in ownership with key management poised to retain stakes. The company has granted exclusivity for due diligence, setting the stage for a possible binding offer.

PYC Therapeutics has secured Safety Review Committee approval to increase dosing in its clinical trial for a novel treatment targeting Autosomal Dominant Optic Atrophy, a rare blinding genetic disease. This milestone marks a significant step forward in the development of PYC-001, a first-in-class RNA therapy.

Etherstack has landed a $1 million contract to supply digital radio network equipment to the world’s largest iron ore producer in Western Australia, reinforcing its growth in recurring revenues. The company also reports record cash receipts in the first half of 2025, signaling strong momentum.

IperionX has secured its first U.S. Army task order worth $1.3 million under a $99 million SBIR Phase III contract, marking a significant step in reshoring titanium production for U.S. defense needs.

Radiopharm Theranostics has secured FDA Fast Track designation for RAD101, a novel imaging agent aimed at improving diagnosis of recurrent brain metastases. The move could speed development and regulatory review as the company advances its Phase 2 clinical trial.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

Kore Potash has signed non-binding term sheets with OWI-RAMS for a $2.2 billion funding package to develop its flagship Kola Potash Project in the Republic of Congo, combining senior secured finance and royalty-based funding under Shariah principles.

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.

Synertec Corporation has signed a 12-month MOU with global battery leader Ritar International to integrate advanced OPzV battery technology into its Powerhouse microgrid system, aiming to slash costs and scale production rapidly.